Improving treatment for Sjögren's disease with a new drug combination
Optimization of a Treatment for Sjögren's Disease Using Aspirin-Triggered Resolvin D1 and Dexamethasone
This study is looking at a new way to help people with Sjögren's disease by testing a combination of two treatments to reduce inflammation and improve saliva production, aiming to find the best dosage for a safer and more effective option.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11005215 on NIH RePORTER |
What this research studies
This research focuses on Sjögren's disease, an autoimmune condition that leads to inflammation and reduced saliva production. The study aims to optimize a treatment combining aspirin-triggered Resolvin D1 and dexamethasone to reduce inflammation and restore salivary gland function. By using mathematical modeling to determine the best dosage, the researchers hope to create a more effective and affordable treatment option. Patients may benefit from a safer and more effective way to manage their symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Sjögren's disease who experience chronic inflammation and reduced saliva production.
Not a fit: Patients with other autoimmune conditions unrelated to Sjögren's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for patients suffering from Sjögren's disease.
How similar studies have performed: Previous studies have shown promise in using similar approaches to treat autoimmune conditions, indicating potential for success in this research.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Baker, Olga Juliana — University of Missouri-Columbia
- Study coordinator: Baker, Olga Juliana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.